Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
Common protocol and shared infrastructure allow for operational and scientific efficiencies

- Regimen: Active Study Drug + Matching Placebo

- 1 Protocol (Phase 2/3)
  - 1 single IRB
  - Central Governance

- 7 Regimens
  - 70+ Enrolling Sites
  - ~1300 Participants

Regimen: Active Study Drug + Matching Placebo
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

Primary Endpoint (Placebo-Controlled Period)
Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival

Safety, Secondary, and Exploratory Endpoints
(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)
Enrollment Update: Regimen F and Regimen G

(As of 5/2/24)

The HEALEY ALS Platform Trial completes enrollment for testing investigational product ABBV-CLS-7262 from Calico Life Sciences

The HEALEY ALS Platform Trial completes enrollment for Regimen G evaluating investigational product DNL343 from Denali Therapeutics

Thank You
for your partnership in ALS research

https://bit.ly/3ChDCq

https://bit.ly/3wUUGI
Navigating Clinical Trial Opportunities

- ClinicalTrials.gov – clinicaltrials.gov/

- ALS TDI Trial Navigator – www.als.net/als-trial-navigator/


- NEALS – neals.org/als-trials/neals-affiliated

- MDA – www.mda.org/research/clinical-trials

- ALSA – www.als.org/research/finding-als-research-opportunities

- International Alliance of ALS/MND Associations – www.als-mnd.org/support-for-pals-cals/research/understanding-als-mnd-research/
Visit the NEALS website to explore upcoming webinars or view previous recordings

https://bit.ly/3S4P0Sb

**May 8, 2024 / 4:00 pm–5:00 pm**

**An Overview of The ALS Better Care Act**

Join Dr. Terry Heiman-Patterson, Dr. Kelly Gwathmey and Dr. Sabrina Paganoni, and as they discuss the importance of multidisciplinary care and the role of the ALS Better Care Act to ensure that quality care at Multidisciplinary Centers...

**May 16, 2024 / 11:00 am–12:00 pm**

**Access for ALL in ALS (ALL ALS) Consortium**

National Institutes of Health (NIH) funded “ALL ALS” consortium is a multi-institutional effort that aims to organize the ALS clinical research landscape in the US. ALL ALS is operating in partnership with several stakeholders...
EAP Webpages and Resources

Link to EAP Website:

https://bit.ly/3uni31c
First Participants Enrolled in the NIH-Funded Pridopidine and Rapa EAPs!

The Sean M. Healey & AMG Center for ALS and Prilenia Therapeutics Announce First Participant Enrolled in NIH-Sponsored ACT for ALS Expanded Access Protocol for Pridopidine

Juliana Araujo · jaraujo5@mgh.harvard.edu

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP)

Juliana Araujo · jaraujo5@mgh.harvard.edu
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:
https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m

Upcoming Webinars:
May 9th - EAP Discussion with Shawn Sarbacker from Tech vs ALS
May 16th - Weekly Q&A webinar
May 23rd - Weekly Q&A webinar